Doms № 1 -2022

PDF

Doms № 2 -2022 (84-91 p)

Microbiota and endocrine-metabolic diseases

Borovets M. O., Urbanovych A. M.

PDF

Download

As of today, about 30% of the global population is overweight or obese, which is almost two and a half times the number of children and adults who are malnourished. If the prevalence of obesity will continue to grow at the same rate, about half of the adult population of the Earth will suffer from obesity by 2030. The intestinal microbiota, depending on its composition, can both stimulate the occurrence of diseases and have a protective effect. Trying to understand pathology, Hindu-forged by microbiota, the article considers several main mechanisms: increased energy accumulation, changes in the regulation of the metabolism of fatty acids, especially butyrate, bile acids, lipopolysaccharides, GABA, the effect on the endogenous cannabinoid system and toll-like receptors and “metabolic endotoxemia”. In this article, we consider disorders, in one way or another associated with metabolic syndrome and insulin resistance, with particular attention paid to obesity and diabetes.

Keywords: intestinal microbiota, endocrine-metabolic diseases, overweight, obesity.

  1. By Richard Dobbs, Corinne Sawers, Fraser Thompson, James Manyika, Peter Child, Sorcha McKenna, and Angela Spatharou. How the world could better fight obesity. 2014
  2. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc. 2010 Aug;69(3):434-41
  3. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F. Gut metagenome in European women with normal, impaired and diabetic
    glucose control. Nature. 2013;498:99–103
  4. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, Gao Z,
    Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488:621–626
  5. Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22:1079–1089
  6. Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr Rev. 2017;39:133–153
  7. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–1023
  8. Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol. 2016;78:277– 299. doi: 10.1146/annurev-physiol-021115-105439
  9. Bogunovic M, Dave SH, Tilstra JS, Chang DT, Harpaz N, Xiong H, Mayer LF, Plevy SE. Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1770–G1783
  10. PalazzoM,BalsariA,RossiniA,SelleriS,CalcaterraC, Gariboldi S, Zanobbio L, Arnaboldi F, Shirai YF, Serrao G, et al. Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion. J Immunol. 2007;178:4296–4303
  11. Hersoug LG, Moller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016;17:297–312
  12. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2:747–756
  13. Balakumar M, Prabhu D, Sathishkumar C, Prabu P, Rokana N, Kumar R, Raghavan S, Soundarajan A, Grover S, Batish VK, et al. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high- fat diet-fed C57BL/6J mice. Eur J Nutr. 2016;57:279–295
  14. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., Liang S., Zhang W., Guan Y., Shen D., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60
  15. Biagi E., Nylund L., Candela M., Ostan R., Bucci L., Pini E., Nikkïla J., Monti D., Satokari R., Franceschi C., et al. Through ageing and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE. 2010;5:e10667
  16. Kimura I., Ozawa K., Inoue D., Imamura T., Kimura K., Mae- da T., Terasawa K., Kashihara D., Hirano K., Tani T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 2013;4:1829
  17. Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C, Franzosa EA, Hübenthal M, Rahnavard A, Frost F, Lloyd-Price J, Schirmer M, Lusis AJ, Vulpe CD, Lerch MM, Homuth G, Kacprowski T, Schmidt CO, Nöthlings U, Karlsen TH, Lieb W, Laudes M, Franke A, Huttenhower C. Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition.Cell Host Microbe.
  18. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4842019 Aug 14;26(2):252-264.e10
  19. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, et al.
  20. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–775
  21. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787–1794
  22. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384
  23. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601– 609
  24. Pearson J.A., Wong F.S., Wen L. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 2016:76–88
  25. Markle J.G., Fish E.N. SeXX matters in immunity. Trends Immunol. 2014:97–104
  26. Markle J.G., Frank D.N., Mortin-Toth S., Robertson C.E., Feazel L.M., Rolle-Kampczyk U., von Bergen M., McCoy K.D., Macpherson A.J., Danska J.S. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084–1088
  27. Yurkovetskiy L., Burrows M., Khan A.A., Graham L., Volchkov P., Becker L., Antonopoulos D., Umesaki Y., Chervonsky A.V. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39:400–412
  28. Vatanen T., Kostic A.D., d’Hennezel E., Siljander H., Franzosa E.A., Yassour M., Kolde R., Vlamakis H., Arthur T.D., Hämäläinen A.M., et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016;165:842–853
  29. Kim H.M., Park B.S., Kim J.I., Kim S.E., Lee J., Oh S.C., Enkhbayar P., Matsushima N., Lee H., Yoo O.J., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130:906–917
  30. Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Novelo L.L., Casella G., Drew J.C., Ilonen J., Knip M., Hyöty H., et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5:82–91
  31. Endesfelder D., Engel M., Davis-Richardson A.G., Ardissone A.N., Achenbach P., Hummel S., Winkler C., Atkinson M., Schatz D., Triplett E., et al. Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome. 2016;4:17
  32. Brown C.T., Davis-Richardson A.G., Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Casella G., Drew J.C., Ilonen J., Knip M., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE. 2011;6:e25792
  33. Knip M., Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2016;12:154–167
  34. Qi, X., Yun, C., Sun, L. et al. Gut microbiota–bile acid–in- terleukin-22 axis orchestrates polycystic ovary syndrome.
    Nat Med 25, 1225–1233 (2019)
  35. Atıcı S., Soysal A., Karadeniz Cerit K., Yılmaz Ş., Aksu B.,
    Kıyan G., Bakır M. Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Med. Mycol. Case Rep. 2017;15:33–35
  36. ,KarvonenM.,Tuomilehto J. Domicrobes have a causal role in type 1 diabetes? Med. Sci. Monit. 2005;11:63–69
  37. Alang N., Kelly C.R. Weight gain after faecal microbiota transplantation. Open Forum Infect. Dis. 2015;2:ofv004